{"id":36256,"date":"2019-05-24T17:39:00","date_gmt":"2019-05-24T15:39:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/"},"modified":"2023-08-24T17:39:36","modified_gmt":"2023-08-24T15:39:36","slug":"ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/","title":{"rendered":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO"},"content":{"rendered":"<p><b>Paris (France), le 24 mai 2019 \u2013 Ipsen (Euronext\u00a0: IPN ; ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que de nouvelles donn\u00e9es issues d\u2019\u00e9tudes cliniques sur des utilisations de ses m\u00e9dicaments en oncologie \u2013 cabozantinib (Cabometyx<\/b><b>\u00ae<\/b><b>), irinot\u00e9can liposomal (Onivyde<\/b><b>\u00ae<\/b><b>) et lanr\u00e9otide autogel (Somatuline<\/b><b>\u00ae<\/b><b>, commercialis\u00e9 sous le nom de Somatuline<\/b><b>\u00ae<\/b><b>\u00a0Depot<\/b><b>\u00ae<\/b><b>\u00a0aux \u00c9tats-Unis) \u2013 seront pr\u00e9sent\u00e9es lors de la r\u00e9union annuelle 2019 de l\u2019<\/b><em><b>American Society of Clinical Oncology<\/b><\/em><b>\u00a0(ASCO), qui se tiendra du 31\u00a0mai au 4\u00a0juin 2019 \u00e0 Chicago, dans l\u2019Illinois.<\/b><br \/>Ipsen pr\u00e9sentera les donn\u00e9es suivantes sur ses m\u00e9dicaments\u00a0:<\/p>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Nouvelles donn\u00e9es de l\u2019essai de phase 3<\/b>\u00a0CELESTIAL sur l\u2019association des \u00e9v\u00e9nements ind\u00e9sirables et des r\u00e9sultats d\u2019efficacit\u00e9 pour le cabozantinib chez les patients atteints de carcinome h\u00e9patocellulaire (CHC) avanc\u00e9<\/li>\n<li style=\"margin-bottom:3px\"><b>Phase 3\u00a0<\/b>COSMIC-312 du cabozantinib en combinaison avec l\u2019atezolizumab versus soraf\u00e9nib chez les patients atteints de carcinome h\u00e9patocellulaire avanc\u00e9 n\u2019ayant pas re\u00e7u de traitement anticanc\u00e9reux syst\u00e9mique ant\u00e9rieur<\/li>\n<li style=\"margin-bottom:3px\"><b>Premi\u00e8res donn\u00e9es de phase 2\u00a0<\/b>de l\u2019\u00e9tude CaboGIST (essai 1317) de l\u2019<em>European Organization for Research and Treatment of Cancer<\/em>\u00a0sur l\u2019activit\u00e9 et la s\u00e9curit\u00e9 du cabozantinib chez les patients atteints de tumeurs stromales gastro-intestinales m\u00e9tastatiques apr\u00e8s \u00e9chec de l\u2019imatinib et du sunitinib<\/li>\n<li style=\"margin-bottom:3px\"><b>R\u00e9sultats pr\u00e9liminaires\u00a0<\/b>de l\u2019\u00e9tude RESILIENT sur l\u2019injection d\u2019irinot\u00e9can liposomal \u00e0 des patients atteints d\u2019un cancer du poumon \u00e0 petites cellules<\/li>\n<li style=\"margin-bottom:3px\"><b>R\u00e9sultats d\u2019une \u00e9tude multicentrique de phase 2\u00a0<\/b>sur le lanr\u00e9otide autogel dans le traitement de sympt\u00f4mes cliniques associ\u00e9s \u00e0 une obstruction intestinale maligne inop\u00e9rable<\/li>\n<\/ul>\n<p>\u00ab\u00a0Chez Ipsen, nos patients sont une source d\u2019inspiration et nous encouragent \u00e0 combattre les cancers les plus difficiles \u00e0 traiter, en particulier ceux pour lesquels les options th\u00e9rapeutiques sont limit\u00e9es. Pour nous, l\u2019ASCO est l\u2019occasion de pr\u00e9senter les progr\u00e8s que nous avons accomplis pour remplir notre mission\u00a0: \u00e9laborer et proposer des solutions th\u00e9rapeutiques qui r\u00e9pondent aux besoins r\u00e9els des patients et qui peuvent contribuer \u00e0 am\u00e9liorer leur vie\u00a0\u00bb, a d\u00e9clar\u00e9 le docteur Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif, R&amp;D et Chief Scientific Officer d\u2019Ipsen. \u00ab\u00a0Gr\u00e2ce \u00e0 nos programmes cliniques et nos diff\u00e9rentes collaborations, nous progressons sans cesse dans le traitement des cancers du rein, du foie et du poumon \u00e0 petites cellules, mais \u00e9galement pour d\u2019autres cancers o\u00f9 les besoins m\u00e9dicaux non satisfaits sont importants. C\u2019est pourquoi nous sommes impatients de poursuivre ces programmes.\u00a0\u00bb<\/p>\n<p>Suivez Ipsen sur Twitter via @IpsenGroup et @IpsenUS et tenez-vous au courant des informations et actualit\u00e9s de l\u2019ASCO 2019 en utilisant le hashtag #ASCO19.<\/p>\n<p><b>Aper\u00e7u des principales pr\u00e9sentations d\u2019Ipsen lors de l\u2019ASCO 2019\u00a0:<\/b><\/p>\n<table style=\"border-collapse: collapse;width:895px;border-collapse:collapse\">\n<tr>\n<td style=\"width:164px\"><b>M\u00c9DICAMENT<\/b><\/td>\n<td style=\"width:350px\"><b>TITRE DE L\u2019ABSTRACT<\/b><\/td>\n<td style=\"width:359px\"><b>NUM\u00c9RO\/HEURE DE L\u2019ABSTRACT (CDT)<\/b><\/td>\n<\/tr>\n<tr>\n<td rowspan=\"3\" style=\"width:164px\"><b>CABOMETYX\u00ae<\/b><b>(CABOZANTINIB)<\/b><b>\u00a0<\/b><b>\u00a0<\/b><\/td>\n<td style=\"width:350px\">Phase 3 (COSMIC-311) randomized, double-blind, placebo-controlled study of cabozantinib in patien4ts with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy<\/td>\n<td style=\"width:359px\">Abstract TPS6097 Poster 82a \u2013 Cat\u00e9gorie\u00a0: Cancer de la t\u00eate et du cou\u00a0; samedi 1er\u00a0juin, 13h15 \u2013 16h15\u00a0; hall ATIP<\/td>\n<\/tr>\n<tr>\n<td style=\"width:350px\">\u00a0<\/p>\n<p>Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the Phase 3 CELESTIAL trial<\/td>\n<td style=\"width:359px\">Abstract 4088 Poster 193 \u2013 Cat\u00e9gorie\u00a0: Cancer gastro-intestinal (non colorectal)\u00a0; lundi 3\u00a0juin, 8h00 \u2013 11h00\u00a0; hall A<\/td>\n<\/tr>\n<tr>\n<td style=\"width:350px\">\u00a0<\/p>\n<p>Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy<\/td>\n<td style=\"width:359px\">Abstract TPS4157 Poster 254a \u2013 Cat\u00e9gorie\u00a0: Cancer gastro-intestinal (non colorectal)\u00a0; lundi 3\u00a0juin, 8h00 \u2013 11h00\u00a0; hall ATIP<\/td>\n<\/tr>\n<tr>\n<td style=\"width:164px\"><b>ONIVYDE\u00ae\u00a0(NAL-IRI \/ IRINOT\u00c9CAN LIPOSOMAL)<\/b><\/td>\n<td style=\"width:350px\">\u00a0<\/p>\n<p>RESILIENT: Study of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer: Preliminary Findings from Part 1 Dose-defining Phase<\/td>\n<td style=\"width:359px\">Abstract 8562 Poster 318 \u2013 Cat\u00e9gorie\u00a0: Cancer du poumon \u2013 Cancers locaux-r\u00e9gionaux non \u00e0 petites cellules\/\u00e0 petites cellules\/autres cancers thoraciques\u00a0; poster\u00a0; dimanche 2\u00a0juin, 8h00 \u2013 11h00\u00a0; hall A<\/td>\n<\/tr>\n<tr>\n<td style=\"width:164px\"><b>SOMATULINE\u00ae\u00a0AUTOGEL\u00ae\u00a0(LANR\u00c9OTIDE AUTOGEL\/DEPOT)<\/b><\/td>\n<td style=\"width:350px\">\u00a0<\/p>\n<p>Efficacy and Safety of Lanreotide Autogel (LAN) 120 mg in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (IMIO): R\u00e9sultats d\u2019une \u00e9tude multicentrique de phase II<\/td>\n<td style=\"width:359px\">Abstract 4118 Poster 223 \u2013 Cat\u00e9gorie\u00a0: Cancer gastro-intestinal (non colorectal)\u00a0; poster\u00a0; lundi 3\u00a0juin, 8h00 \u2013 11h00\u00a0; hall\u00a0A<\/td>\n<\/tr>\n<\/table>\n<p><b>Aper\u00e7u des principales pr\u00e9sentations d\u2019\u00e9tudes parrain\u00e9es par l\u2019investigateur concernant les m\u00e9dicaments Ipsen lors de l\u2019ASCO 2019\u00a0:<\/b><\/p>\n<table style=\"border-collapse: collapse;width:890px;border-collapse:collapse\">\n<tr>\n<td style=\"width:168px\"><b>M\u00c9DICAMENT<\/b><\/td>\n<td style=\"width:358px\"><b>TITRE DE L\u2019ABSTRACT<\/b><\/td>\n<td style=\"width:364px\"><b>NUM\u00c9RO\/HEURE DE L\u2019ABSTRACT (CDT)<\/b><\/td>\n<\/tr>\n<tr>\n<td rowspan=\"3\" style=\"width:168px\"><b>CABOMETYX\u00ae<\/b><b>(CABOZANTINIB)<\/b><b>\u00a0<\/b><\/td>\n<td style=\"width:358px\">Activity and safety of cabozantinib in patients with metastatic gastrointestinal stromal tumor after failure of imatinib and sunitinib. European Organization for Research and Treatment of Cancer (EORTC) Phase 2 trial 1317 \u00ab\u00a0CaboGIST\u00a0\u00bb<em>Essai sponsoris\u00e9 par EORTC<\/em><\/td>\n<td style=\"width:364px\">Abstract 11006 Oral\u00a0: Cat\u00e9gorie\u00a0: Sarcome\u00a0; lundi 3\u00a0juin, 10h00 \u2013 10h12\u00a0; E450<\/td>\n<\/tr>\n<tr>\n<td style=\"width:358px\">\u00a0<\/p>\n<p>PDIGREE: An adaptive Phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated Renal Cell Cancer (Alliance A031704)<em>Essai sponsoris\u00e9 par NCI<\/em><\/td>\n<td style=\"width:364px\">Abstract TPS4596 Poster 417a \u2013 Cat\u00e9gorie\u00a0: Cancer g\u00e9nito-urinaire (non prostatique)\u00a0; poster\u00a0; lundi 3\u00a0juin, 13h15 \u2013 16h15\u00a0; hall\u00a0A<\/td>\n<\/tr>\n<tr>\n<td style=\"width:358px\">\u00a0<\/p>\n<p>Prognostic value of sequential 18F-FDG + Na18F PET\/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with Cabozantinib\/ Nivolumab +\/- Ipilimumab (CaboNivoIpi)<em>Essai sponsoris\u00e9 par NCI<\/em><\/td>\n<td style=\"width:364px\">Abstract 4544 Poster 370 \u2013 Cat\u00e9gorie\u00a0: Cancer g\u00e9nito-urinaire (non prostatique)\u00a0; poster\u00a0; lundi 3\u00a0juin, 13h15 \u2013 16h15\u00a0; hall\u00a0A<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px\">\u00a0<\/td>\n<td style=\"width:358px\">\u00a0<\/p>\n<p>Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +\/- ipilimumab (CaboNivoIpi)<\/td>\n<td style=\"width:364px\">Abstract 4555 Poster 381 \u2013 Cat\u00e9gorie\u00a0: Cancer g\u00e9nito-urinaire (non prostatique)\u00a0; poster\u00a0; lundi 3\u00a0juin, 13h15 \u2013 16h15\u00a0; hall\u00a0A<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px\">\u00a0<\/td>\n<td style=\"width:358px\">\u00a0<\/p>\n<p>Correlates of overall survival (OS) in metastatic vs. primary uveal melanoma (UM) and results of a randomized trial of cabozantinib (cabo) vs. chemotherapy (chemo) Alliance A091201<em>Essai sponsoris\u00e9 par NCI<\/em><\/td>\n<td style=\"width:364px\">Abstract 9506 \u2013 Oral\u00a0: Cat\u00e9gorie\u00a0: M\u00e9lanome\/Cancers de la peau\u00a0; poster\u00a0; mardi 4\u00a0juin, 11h45 \u2013 11h57\u00a0; S406<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px\"><b>ONIVYDE\u00ae\u00a0(NAL-IRI \/ IRINOT\u00c9CAN LIPOSOMAL)<\/b><\/td>\n<td style=\"width:358px\">\u00a0<\/p>\n<p>A multicenter phase Ib\/II study of nalirinotecan, 5fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer<\/td>\n<td style=\"width:364px\">Abstract TPS4154 Poster 252b \u2013 Cat\u00e9gorie\u00a0: Cancer gastro-intestinal (non colorectal)\u00a0; poster\u00a0; lundi 3\u00a0juin, 8h<\/td>\n<\/tr>\n<\/table>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=SivvpH5aURVcUEBLZSUq1mtpzUOfbSD_AH_hfj2m2ClZCsAhht72TxC5Lx-TAX_SHIM33a1Y5K_RkeeP_DEkiCXU-2hLFbslIjId9ieI7wgCcMphw9j192xjvYY4056psWtEWc9txS_RwMXScawxDv2Qmp_N5lhlDiVnk6sCGT28LkkAJxbMriBsvP06VX6s\" title=\"ASCO-Curtain-Raiser_FR\" rel=\"nofollow noopener\">ASCO-Curtain-Raiser_FR<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556],"tags":[],"class_list":["post-36256","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T15:39:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO\",\"datePublished\":\"2019-05-24T15:39:00+00:00\",\"dateModified\":\"2023-08-24T15:39:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\"},\"wordCount\":1035,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\",\"name\":\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2019-05-24T15:39:00+00:00\",\"dateModified\":\"2023-08-24T15:39:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/","og_site_name":"Global","article_modified_time":"2023-08-24T15:39:36+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO","datePublished":"2019-05-24T15:39:00+00:00","dateModified":"2023-08-24T15:39:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/"},"wordCount":1035,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/","name":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2019-05-24T15:39:00+00:00","dateModified":"2023-08-24T15:39:36+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTRmMzI2ZjUtMjhhOS00M2ZmLWE3ZWEtODBlNjFkMjA0ZWMyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-cliniques-sur-son-portefeuille-en-oncologie-pour-11-types-de-tumeurs-solides-lors-de-la-reunion-annuelle-2019-de-lasco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es cliniques sur son portefeuille en oncologie pour 11 types de tumeurs solides lors de la r\u00e9union annuelle 2019 de l\u2019ASCO"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36256\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}